



**Vaccines and Global Health: The Week in Review**  
**15 March 2025 :: Issue 790**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

Milestones, Perspectives


.....  
.....

Sudan


The UN Secretary-General recently described the situation in Sudan as a “crisis of staggering scale and brutality.”

Public Health Situation Analysis: Sudan conflict (10 March 2025) - WHO

Nearly two years into the conflict, Sudan faces an **unprecedented humanitarian health crisis, with 30.4 million people—over half the population—requiring assistance in 2025**, including 16 million children...**Disease outbreaks, including cholera, malaria, and measles, are spreading**. WHO is supporting emergency response efforts, but insecurity, displacement, and resource shortages continue to hinder healthcare delivery across the country...



World Health Organization







Sudan Conflict and Complex Emergency

Date: 10 March 2025

Public Health Situation Analysis (PHSA)

This is the third WHO PHSA on the Sudan crisis. This updates the September 2024 version.

Typologies of emergency	Main health threats	WHO grade	Security level (UNDSS) <sup>1</sup>	INFORM (2025) <sup>2</sup>
<div>  <div>Conflict</div> </div> <div>  <div>Food Security</div> </div> <div>  <div>Displacement</div> </div> <div>  <div>Epidemics</div> </div>	<ul style="list-style-type: none"> <li>Malnutrition</li> <li>Trauma and injury</li> <li>Cholera and acute watery diarrhoea</li> <li>Dengue</li> <li>Malaria</li> <li>Measles</li> <li>Non-communicable diseases</li> <li>Mental health</li> <li>Protection (including gender-based violence)</li> </ul>	<b>Grade 3</b> (IASC System-Wide Scale-Up activated)	<b>High (5/6):</b> Khartoum  <b>Substantial (4/6):</b> North Kordofan, Northern, River Nile, Port Sudan (Red Sea), Kassala, Gedaref, Al Jazirah, White Nile, Sennar, North Darfur, Central Darfur, East Darfur, South Kordofan, West Kordofan, South Darfur, West Darfur.  <b>Moderate (3/6):</b> Blue Nile	<b>Risk Index (0-10):</b> 7.4 (Very High)  <b>Global Ranking (1-191 countries):</b> 8

SUMMARY OF CRISIS AND KEY FINDINGS

Nearly two years since the escalation of the conflict, Sudan continues to experience a humanitarian crisis of epic proportions. The country faces an unprecedented humanitarian crisis, with 30.4 million people—over half the population—requiring assistance in 2025. Of the total population affected, 16

million are children. The humanitarian crisis has led to a substantial health crisis.

**The Sudan conflict is the world’s largest and fastest-growing displacement crisis.** It is also one of the largest protection crises facing the world today. An estimated 12.8 million people have been forcibly displaced as of March 2025, including over 8.8 million newly displaced internally and over 3.7 million refugees, asylum seekers, and returnees who have crossed Sudan’s borders into neighbouring countries...

**Sudan ranks among the top four countries globally for the prevalence of global acute malnutrition,** at an estimated 13.6%. A staggering 4.9 million children under five years, along with pregnant and nursing women, were estimated to be acutely malnourished in 2024, marking a 22% increase compared to 2023.<sup>7</sup> Given the high rates of malnutrition, a debilitated health system and low immunization coverage, disease outbreaks will continue to have catastrophic impacts, particularly for children...

SUDAN: KEY HEALTH RISKS IN THE COMING THREE – FOUR MONTHS		
Public health risk	Level of risk	Rationale
Cholera and acute watery diarrhoea (AWD)		Sudan declared a cholera outbreak in August 2024 after confirmation of toxigenic <i>Vibrio cholerae</i> in samples from Kassala in July 2024. Fuelled by heavy rains and flooding, coupled with intensified conflict, subsequent internal displacement that brought overcrowding, and lack of access to clean water in displacement sites and communities, the outbreak has spread to 12 states with 88 localities, with over 57 100 cases and 1500 deaths reported, as of 3 March 2025. <sup>87</sup> Oral cholera vaccination (OCV) reactive campaigns have targeted eight states, reaching 7.4 million people between 19 August 2024 and 5 January 2025. <sup>88</sup> Cholera has a long history in Sudan, characterized by recurrent outbreaks driven by conflict, environmental factors, inadequate water, sanitation and hygiene (WASH), and weak health infrastructure.
Dengue		The current dengue fever outbreak started in July 2024, and as of 3 March 2025, there have been 10 464 cases and 16 deaths across nine states and 36 localities. Khartoum and Kassala have been the most affected. The spread of vector-borne diseases like dengue is unsurprising, due to climate change, deterioration of routine vector control, poor waste management, and shortage of water supply. Co-occurrence of vector-borne diseases may lead to more severe illnesses.
Malaria		Malaria has remained stagnant on the list of the top ten causes of illness in Sudan, accounting for around 20% of outpatient department attendance and hospital admission in the country; hence, it remains a national health priority. <sup>89</sup> In November 2024, malaria vaccines were introduced for the first time in Sudan to curtail the impact of the disease. About 186 000 doses targeting 148 000 children across 15 localities in Gedaref and Blue Nile were administered. Efforts are underway to extend vaccination coverage to 129 localities. <sup>90</sup> In 2024, a total of more than 2.54 million malaria cases with 128 associated deaths were recorded across 16 states in the country.
Measles		The current measles outbreak began in 2023. Between January 2024 and 14 February 2025, 903 cases with 13 deaths (CFR: 1.4%) have been reported from 13 States. In addition, there have been reports of suspected measles in Central Darfur, South Darfur, and East Darfur through the EWARS Mobile system. There is low immunization coverage, particularly in hard-to-reach areas. The risk of measles outbreaks is particularly very high for mobile populations, including IDPs, refugees, and any others in camp settings. This risk is further exacerbated by limited access to vaccination.

... **Vaccination coverage:** Before the escalation of the conflict, Sudan had witnessed a remarkable improvement in routine vaccination coverage over the prior few years. This was a result of the stable implementation of routine immunization for the prevention and control of vaccine-preventable childhood diseases.<sup>76</sup> The routine immunization programme in Sudan had good political support, which has been translated into modest financial support. <sup>77</sup>

Since the conflict began in April 2023, health infrastructure and immunization services have been disrupted. Hundreds of thousands of children have been left unvaccinated and at risk of infection from vaccine-preventable diseases, such as measles and polio. This situation is made worse by the displacement of large numbers of people.<sup>78</sup> Sudan, Yemen, and Syria are home to nearly 87% of the total zero-dose children in the region, with Sudan alone contributing 42% of these zero-dose children...

.....  
.....

## Measles

### European Region reports highest number of measles cases in more than 25 years – UNICEF, WHO/Europe

*127 350 measles cases reported in the European Region for 2024 – double the number reported for 2023 and the highest number seen in the Region since 1997*

Geneva/Copenhagen, 13 March 2025

According to an analysis by WHO and the United Nations Children’s Fund (UNICEF), **127 350 measles cases were reported in the European Region for 2024, double the number of cases reported for 2023 and the highest number since 1997.**

**Children under 5 accounted for more than 40% of reported cases in the Region** – comprising 53 countries in Europe and central Asia. More than half of the reported cases required hospitalization. A total of 38 deaths have been reported, based on preliminary data received as of 6 March 2025. Measles cases in the Region have generally been declining since 1997, when some 216 000 were reported, reaching a low of 4440 cases in 2016. However, a resurgence was seen in 2018 and 2019 – with 89 000 and 106 000 cases reported for the 2 years respectively. Following a backsliding in immunization coverage during the COVID-19 pandemic, cases rose significantly again in 2023 and 2024. Vaccination rates in many countries are yet to return to pre-pandemic levels, increasing the risk of outbreaks.

**“Measles is back, and it’s a wake-up call. Without high vaccination rates, there is no health security.** As we shape our new regional health strategy for Europe and central Asia, we cannot afford to lose ground. Every country must step up efforts to reach under-vaccinated communities,” warned Dr Hans Henri P. Kluge, WHO Regional Director for Europe. “The measles virus never rests – and neither can we.” ...

...**Measles remains a significant global threat.** In 2024, 359 521 cases of measles were reported worldwide. Transmission of the virus across borders and continents occurs regularly, and outbreaks of this highly infectious disease will occur wherever the virus finds pockets of un- or under-vaccinated people, particularly children.

.....

## **Data from MSF facilities records one child has died from measles each day in Afghanistan in 2025 – Médecins Sans Frontières**

*Press Release* 12 Mar 2025

- **Our teams in Afghanistan are reporting an alarming surge of measles at three hospitals where we provide support.**
- We have seen nearly 4,799 children suspected of having measles in the first eight weeks of 2025 at these three hospitals.
- **Community-level, rapid, targeted vaccination in the districts most affected by ongoing outbreaks would help reduce the number of measles cases**, and in turn free up hospital beds for children with less preventable conditions.

.....

## **Measles outbreaks in the Americas: PAHO calls for strengthened vaccination and surveillance**

Washington, D.C., 3 March 2025 (PAHO) – The Pan American Health Organization (PAHO) has **issued an epidemiological alert due to an increase in measles cases in several countries in the Americas...**

.....  
.....

## **mPox – PHEIC**

### **Multi-country outbreak of mpox, External situation report #48 - 10 March 2025**

#### ***Highlights***

:: Following the convening of the Emergency Committee under the International Health Regulations (2005) (IHR) on 25 February 2025, the WHO Director-General determined that the ongoing upsurge of mpox continues to be a public health emergency of international concern (PHEIC). The WHO Director-General issued a revised set of temporary recommendations to this effect.

:: The rapid risk assessment of the overall public health risk posed by mpox was updated on 24 February 2025. The overall public health risk posed by mpox was assessed as moderate at the global level...

#### **5. Access to and delivery of countermeasures**

##### ***Access and Allocation Mechanism (AAM)***

##### ***Vaccines***

:: WHO continues to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries in at-risk groups, in support of controlling the surge in mpox cases on the African continent.

:: A total of 1 137 300 doses have been allocated in two rounds to 12 countries (Angola, the Central African Republic, Côte d'Ivoire, the Democratic Republic of the Congo, Guinea, Kenya, Liberia, Nigeria, Rwanda, Sierra Leone, South Africa, and Uganda)

:: To date, 816 580 vaccine doses have been delivered to eight countries, including 50 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January 2025.

:: Vaccination activities have started in four countries (, Democratic Republic of the Congo, Nigeria, Rwanda, and Uganda).

:: On 22 February 2025, the Democratic Republic of the Congo launched their accelerated mpox vaccination activities for 10 days in Kinshasa, aligned with the revised vaccination strategy, targeting more than 660 000 people including 337 000 children aged one to 17 years old.



:: Bavarian Nordic's position on product liability: When national regulatory authorities allow age indications which are not on the label of the product (e.g. 1 year and above, or 12 years and above) in the Marketing Authorization (MA) or Emergency Use Authorization (EUA)., Bavarian Nordic covers the product liability as per the authorized indicated age groups.

:: The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

.....  
.....

## Polio – PHEIC

### Polio this week – 12 March 2025

#### **Headlines**

:: ***Dr Jamal Ahmed appointed WHO Director for Polio Eradication and Chair of GPEI Strategy Committee*** – Dr Ahmed is a long-time polio eradicator, having served since 2022 as

Coordinator of WHO's Africa Regional Office (AFRO) Polio Eradication Programme, based in Brazzaville, Republic of the Congo. Prior to that, he worked for WHO's polio eradication programme in Geneva as Team Lead for Surveillance, Lab and Data, and as Chair of the Global Polio Eradication Initiative's (GPEI) Surveillance Group. He has also served in the WHO Pakistan Country Office as Coordinator of the Polio Team and as the lead for the Risk Assessment and Decision Support Unit. Dr Ahmed takes over this critical role in the polio eradication programme, following the sudden and tragic passing of previous director Aidan O'Leary in August 2024. His notable expertise and experience, in particular at regional and country level, will be crucial in helping drive the partnership towards successful implementation of its strategies, to secure a lasting world free of all forms of poliovirus. [More](#).

:: ***Polio at EIB Group Forum 2025***: last week, at the European Investment Bank (EIB) Group Forum in Luxembourg, Ted Chaiban (Deputy Executive Director, UNICEF), Mike Ryan (Deputy Director General, WHO), Sania Nishtar (CEO, Gavi) and Thomas Östros (Vice President, EIB) took part in a [panel on global health partnerships](#), including the GPEI, and their value in overcoming barriers in global health. Immediately afterwards, a dedicated session on polio featured remarks from WHO, UNICEF and Gates Foundation leadership.

:: ***Expert groups convene on polio eradication***. The Strategic Advisory Group of Experts on immunization ([SAGE](#)) is meeting this week at WHO in Geneva, following last week's meeting of the IHR Emergency Committee on Polio Eradication ([IHR EC](#)). Among a wide range of immunization topics, SAGE is expected to review the global poliovirus epidemiology and current status of bivalent OPV cessation planning and preferred routine immunization schedule with whole-cell pertussis hexavalent vaccine; while the IHR EC reviewed latest international detections of WPVs and cVDPVs. The reports from both meetings will be published over the coming weeks.

:: ***Breakthrough in next-generation polio vaccines***: researchers have taken a major step towards producing a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). Such new technologies could make for ideal tools especially for the post-eradication era, with the aim of having cost-effective vaccines available in an equitable manner. [More](#).

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Pakistan: 18 WPV1-positive environmental samples
- Chad: three cVDPV2 cases and three cVDPV2-positive environmental samples
- DR Congo: one cVDPV2 case
- Nigeria: three cVDPV2 cases
- Occupied Palestinian territory: three cVDPV2-positive environmental samples
- Tanzania: two cVDPV2-positive environmental samples

.....

.....

***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....

.....

**WHO & Regional Offices** [to 15 Mar 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

8 March 2025 *News release*

**[Many pregnancy-related complications going undetected and untreated – WHO](#)**

6 March 2025 *News release*

**[WHO announces new collaborating centre on AI for health governance](#)**

The World Health Organization (WHO) today designated the Digital Ethics Centre at Delft University of Technology in the Netherlands as a WHO Collaborating Centre on artificial intelligence (AI) for health governance...

The WHO Collaborating Centre designation recognizes the Digital Ethics Centre at Delft University of Technology's decades-long history of cutting-edge research on responsible innovation, and its leadership in incorporating ethical values into design requirements for digital technologies. This inauguration marks the continuation of a strong partnership between the Digital Ethics Centre and WHO with the two entities jointly organizing international consultations, workshops, and the development of normative guidance and training in the past...

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

:: 13 March 2025

**[Tanzania declares end of Marburg virus disease outbreak](#)**

**WHO Region of the Americas PAHO**

:: 11 Mar 2025

**[PAHO Director meets with newly elected OAS Secretary General Albert Ramdin to discuss the Interamerican System and health priorities in the Americas](#)**

Washington, DC, March 11, 2025 (PAHO) — The Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, met with Albert Ramdin, newly elected Secretary General of the Organization of American States (OAS), following his election during the 56th Special Session of the OAS General Assembly in Washington, D.C. Ramdin, from Suriname,...

**WHO South-East Asia Region SEARO**

:: 13 March 2025 *News release*

**[WHO South-East Asia Region enhancing multi-source surveillance to strengthen response to health emergencies](#)**

**WHO European Region EURO**

:: 13 March 2025 *Media release*

**European Region reports highest number of measles cases in more than 25 years – UNICEF, WHO/Europe**

**WHO Eastern Mediterranean Region EMRO**

:: 12 March 2025

**Afghanistan's new National Health Policy (2025–2030): a roadmap to a healthier future**

**WHO Western Pacific Region**

*No new digest content identified.*

.....

**WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

**Multi-country outbreak of mpox, External situation report #48 - 10 March 2025**

...Following the convening of the Emergency Committee under the International Health Regulations (2005) (IHR) on 25 February 2025, the WHO Director-General determined that the ongoing upsurge of mpox continues to be a public health emergency of international concern (PHEIC).

**Public Health Situation Analysis: Sudan conflict (10 March 2025)**

*Overview*

Nearly two years into the conflict, Sudan faces an unprecedented humanitarian health crisis, with 30.4 million people—over half the population—requiring assistance in 2025, including 16 million children. The conflict has caused the world's largest and fastest-growing displacement crisis, with 12.8 million forcibly displaced.

.....

**Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

**13 March 2025 | Marburg virus disease– United Republic of Tanzania**

**13 March 2025 | Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia**

.....

**Weekly Epidemiological Record**

2025, Vol. 100, No. 11, pp. 87–90 14 March 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

PDF: <https://iris.who.int/bitstream/handle/10665/380785/WER10011-eng-fre.pdf>

:: Egypt and Georgia certified as malaria-free by WHO

.....

**New WHO Publications**

<https://www.who.int/publications>

*Selected*



13 March 2025

**[Pandemic influenza severity assessment \(PISA\): a WHO guide to assess the severity of influenza in I epidemics and pandemics, second edition](#)**

Download (670.7 kB)

*Overview*

The updated WHO pandemic influenza severity assessment (PISA) framework set out in this document provides a systematic approach for interpreting data collected through existing surveillance systems and improving their usefulness for risk communication and decision-making. The approach enables the severity of current influenza and syndromic respiratory illness activity to be assessed relative to previous years by using historical data to set thresholds that then allow for the qualitative categorization of such activity. PISA is designed to be implemented continuously based on stable/routine reporting systems, enabling activity during epidemic and pandemic periods to be compared. Information to assess severity especially early and throughout the course of a pandemic will also be provided through investigations, studies and modelling.

12 March 2025

**[Strengthening the delivery of HIV testing services and linkage to care during pregnancy and postpartum...](#)**

11 March 2025

**[Subregional networks of antimalaria drug efficacy and resistance in Eastern Africa and Horn of Africa...](#)**

11 March 2025

**[Integration of HIV and syphilis testing services as part of mpox response: standard operating procedures](#)**

11 March 2025

**[Regional Workshop on implementation of good reliance practices for vaccines regulation based on emerging novel technologies](#)**

*Overview*

The WHO Regional Office for South-East Asia had organized a four-day regional hybrid workshop on implementation of good reliance practices for vaccines regulation based on emerging novel technologies, in Pune, India, for the national regulatory authorities (NRAs) of Member States.

COVID-19 vaccines produced through mRNA and other novel technologies have introduced many challenges for vaccine regulation such as approving facilities for multiproduct manufacturing. Approval of these new vaccines requires application of novel approaches with regulatory inspections and dossier assessment by the NRAs. NRAs, especially of non-vaccine producing countries, have limited resources and expertise for vaccine regulation. They must thus rely on other NRAs and NCLs for expedited and effective vaccine regulation to ensure timely and sufficient availability of vaccines for immunization programmes, including pandemic situations. This workshop was focused on supporting the NRAs in the Region to build expertise with good reliance practices (GRP) in the regulation of vaccines.

Key takeaways from the workshop were training of Member State NRA staff on conducting virtual GMP inspections of vaccines produced through novel technologies including joint review of marketing authorization (MA) dossiers. This report provides an overview of the proceedings and action points from the workshop.

11 March 2025

**[Regional stakeholder meeting on the response to antimalarial drug resistance in Africa: meeting report,...](#)**

11 March 2025

[Extending the WHO scheme for external quality assessment of nucleic acid amplification testing for monitoring antimalarial drug resistance: meeting report, 14 July 2023](#)

.....  
.....

**USA – HHS, FDA, CDC+**

***Editor's Note:***

*We employ bolded red text below to identify observations we assess might be useful to readers.*

**HHS**

*News*

*No new digest content identified.*

**FDA**

*Press Announcements*

[FDA Roundup: March 14, 2025](#)

**:: On Thursday, the FDA posted information on the flu vaccine composition for the 2025-2026 U.S. flu season.** The agency, in consultation with our federal partners, reviewed the available data and made its recommendations to manufacturers of the U.S.-licensed influenza vaccines for the production of updated vaccines for the 2025-2026 flu season. Based on this timing, the agency does not anticipate any impact on vaccine supply or timing of availability....

[Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season - FDA](#)

03/13/2025

Today, the FDA made recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 U.S. flu season following a thorough and comprehensive review of U.S. and global surveillance data. With today's action, the FDA does not anticipate any impact on timing or availability of vaccines for the American public. The recommendations are similar to the previous year's strain selection.

**To inform the selection of the flu virus strains, the FDA convened a meeting of scientific and public health experts from the FDA, Centers for Disease Control and Prevention and Department of Defense** for this in-depth discussion. During the meeting, these federal partners collaboratively evaluated and analyzed U.S. and global surveillance data related to the epidemiology and antigenic characteristics of flu viruses currently circulating....

**FDA VRBPAC**

*Advisory Committee Calendar*

***The Advisory Committee calendar does not list any future scheduled meetings of any FDA advisory committee, including VRBPAC.***

**CDC/ACIP [U.S.]** [to 15 Mar 2025]

<http://www.cdc.gov/media/index.html>

*Latest News*

*No new digest content identified.*

**ACIP Meetings** [to 15 Mar 2025]

*Next ACIP Meeting*

[ACIP Meeting February 26-28, 2025 Postponed](#)

"The ACIP meeting will be postponed to accommodate public comment in advance of the meeting. The ACIP workgroups met as scheduled this month and will present at the upcoming ACIP meeting."

Agenda for February 26-28

**[Agenda appears stable from earlier agenda versions]**

### **National Vaccine Program**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**No 2025 meeting dates posted.**

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

**March 13, 2025 / No. 8**

PDF of this issue

:: Human Cases of Highly Pathogenic Avian Influenza A(H5N1) — California, September–December 2024

.....

.....

## **Europe**

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

**First vaccine against epizootic haemorrhagic disease recommended for approval**

The vaccine will protect cattle from outbreaks, protect animal health and prevent economic losses  
14 March 2025

**Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025**

PRAC carried out its broad range of responsibilities for managing the risks associated with medicine use

14 March 2025

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*News*

**Measles on the rise again in Europe: time to check your vaccination status**

11 Mar 2025

*Assessment*

**ECDC assessment of public health workforce capacity in prevention and control of infectious diseases in the EU/EEA**

13 Mar 2025

Report on the findings of a survey on public health workforce capacity in the field of prevention and control of infectious diseases in the EU/EEA.

*Surveillance and monitoring*

**Monthly measles and rubella monitoring report - February 2025**

11 Mar 2025

This report provides an overview of measles and rubella cases reported to ECDC through The European Surveillance System (TESSy).

.....  
.....

**Africa CDC** [to 15 Mar 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

**Newly Launched African Epidemic Fund to Strengthen Health Security**

11 March 2025

**Traditional Healers Join Tanzania's Marburg Response**

9 March 2025

**Funding Options for Health Products Manufacturing in Africa Tabled**

9 March 2025

.....

**China CDC+**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 15 Mar 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 15 Mar 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC**

**CCDC Weekly Reports: Current Volume (7)**

**2025-03-14 / No. 11**

[PDF of this issue](#)

- [Preplanned Studies: Two-Year Surveillance of Dengue, Zika, and Chikungunya Viruses Among Chinese Blood Donors — Guangxi and Yunnan PLADs, China, 2022–2023](#)
- [Preplanned Studies: Developing Machine Learning Models Based on Clinical Manifestations to Predict Influenza — Chongqing Municipality, China, 2022–2023](#)
- [Preplanned Studies: Infodemic Management and Public Health Emergency Preparedness Capacities — Khyber Pakhtunkhwa, Pakistan, 2024](#)

.....  
.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 15 Mar 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 15 Mar 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*Statement* Mar 12, 2025

**Mark Suzman's Statement on the important role of US Federal Government in Education**

Every child growing up in America deserves a high-quality education that equips them with the knowledge, skills, and opportunities they need to thrive. The U.S. federal government plays a vital role in ensuring that students and teachers—regardless of zip code—have the resources they need to succeed by providing funding to schools serving low-income communities, expanding access to affordable college opportunities, and using data to drive smart education policies. The administration must put a real plan in place to continue this important work. Without it, students, communities, and our nation's economy will face devastating consequences.

**Bill & Melinda Gates Medical Research Institute** [to 15 Mar 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 15 Mar 2025]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Chan Zuckerberg Initiative** [to 15 Mar 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 15 Mar 2025]

<http://cepi.net/>

*CEPI News, Blog*

*News*

**Nagasaki University's 'Nanoball' technology could help defeat the next Disease X**

OSLO/ NAGASAKI, JAPAN, 10 March 2025—A new 'nanoball' vaccine platform developed by experts in Japan will be tested as part of new research, supported by CEPI, looking for promising tools that could help fight an infectious disease outbreak with pandemic potential.

Researchers at Nagasaki University have developed the pioneering innovation as a novel approach to aid the delivery of messenger RNA (mRNA) vaccines in the body...

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 15 Mar 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 15 Mar 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [to 15 Mar 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 15 Mar 2025]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 15 Mar 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 15 Mar 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 15 Mar 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*



**Fondation Merieux** [to 15 Mar 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 15 Mar 2025]

<https://www.gavi.org/>

*Press Releases*

14 March 2025

**Gavi welcomes first-ever prequalification of a maternal RSV vaccine**

Geneva, 13 March 2025 – Gavi, the Vaccine Alliance welcomes the first-ever prequalification [Abrysvo, Pfizer Europe MA EEIG] of a maternal respiratory syncytial virus (RSV) vaccine to protect infants by the World Health Organization (WHO). This is an important step towards curbing one of the leading causes of acute lower respiratory infections in children globally...

**GE2P2 Global Foundation** [to 15 Mar 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 21 Feb 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – February 2025](#)

**GHIT Fund** [to 15 Mar 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

March 5, 2025

**GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children**

**Global Fund** [to 15 Mar 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 15 Mar 2025]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 15 Mar 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 15 Mar 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 15 Mar 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 15 Mar 2025]

<https://www.iavi.org/>

*Press Releases, Features*

*No new digest content identified.*

**INSERM** [to 15 Mar 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

13 March 2025

**[ICMRA PQKMS Collaborative Hybrid Inspection Pilot Summary Report](#)**

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 15 Mar 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

14 March 2025

**[ICH M13B Draft Guideline & Step 2 Presentation Now Available on the ICH Website](#)**

The ICH M13B draft Guideline on Bioequivalence for Immediate-Release Solid Oral Dosage Forms – Additional Strengths Biowaiver reached Step 2b of the ICH Process on 13 March 2025 and entered the public consultation period.

14 March 2025

**[ICH M11 Updated Technical Specification Document Now Available on the ICH Website](#)**

The ICH M11 updated version of the Technical Specification document, which incorporates comments received during the first public consultation, reached Step 2b of the ICH process in March 2025 and now enters the second round of public consultation. [M11 EWG Clinical electronic Structured Harmonised Protocol (CeSHarP)]

**ICRC** [to 15 Mar 2025]

<https://www.icrc.org/en/whats-new>

*Latest press releases and statements [Selected]*

*News release 10-03-2025*

**Israel and the occupied territories: ICRC warns of worsening humanitarian crisis in Gaza**

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 15 Mar 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 11/03/2025*

**Statement: Gaza's humanitarian crisis deepens as aid dwindles and power cuts bite**

**IPPS - International Pandemic Preparedness Secretariat** [to 15 Mar 2025]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [to 15 Mar 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 15 Mar 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**19th International Congress of Immunology**

Vienna, August 17-22, 2025.

**IVAC** [to 15 Mar 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 15 Mar 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 15 Mar 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières**\_[to 15 Mar 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Afghanistan*

**[Data from MSF facilities records one child has died from measles each day in Afghanistan in 2025](#)**

*Press Release 12 Mar 2025*

*Gaza-Israel war*

**[Israeli authorities must stop use of aid as a tool of war in Gaza](#)**

*Press Release 11 Mar 2025*

**National Academy of Medicine** - USA [to 15 Mar 2025]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 15 Mar 2025]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

**NIH** [to 15 Mar 2025]

<http://www.nih.gov/>

*News Releases*

**[Tecovirimat is safe but ineffective as treatment for clade II mpox](#)**

March 12, 2025 — NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

**PATH** [to 15 Mar 2025]

<https://www.path.org/media-center/>

*Newsroom [Selected]*

**[PATH welcomes maternal RSV vaccine WHO prequalification](#)**

The milestone marks the first-ever prequalification of an RSV vaccine and paves the way for improving respiratory disease prevention for infants around the world.

Published: March 2025 Statement

### **PATH launches new Center for Policy and Advocacy**

The new Center enhances collaboration between PATH's technical and advocacy experts, boosting our ability to expand access to lifesaving health care through policy.

Published: March 2025 Press Release

### **PATH launches clinical trial on the use of artificial intelligence in primary health care**

The Nairobi-based trial aims to build evidence for whether AI can improve quality of care, by reducing instances of incorrect or missed diagnoses, spare patients unnecessary repeat visits, and ensure guideline-based treatment plans.

### **Sabin Vaccine Institute** [to 15 Mar 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

### **UNAIDS** [to 15 Mar 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Feature Story*

### **Impact of US funding cuts on the global AIDS response — Weekly update 10 March 2025**

12 March 2025

This weekly update summarizes reports on the impact of US funding cuts on national AIDS responses from 20 UNAIDS Country Offices received during the week of 3-7 March 2025. These reports show that an increasing number of US-funded implementing partners—including in Botswana, South Africa and Zambia—have received notices that their funding awards have been terminated. In some cases, these notices have led to the closure of HIV services that had previously been allowed to operate under terms of waivers.

### **UNICEF** [to 15 Mar 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Remarks* 14 March 2025

### **Geneva Palais briefing note: Children in Sudan: a generation at risk**

GENEVA/NEW YORK, 14 March 2024 – "This morning, I would like to bring your attention to Sudan's children—trapped in one of the world's worst humanitarian crises. I returned last week from a country where conflict, displacement, and hunger are destroying young lives. "More than 16 million children in Sudan urgently...

*Remarks* 13 March 2025

### **UNICEF Executive Director Catherine Russell's remarks at UN Security Council meeting on Sudan**

NEW YORK, 13 March 2025 - "Excellencies, colleagues, thank you for inviting me to speak here today. "I'd like to express my appreciation to Denmark and to the United Kingdom for convening and hosting this briefing during Denmark's presidency of the Security Council. I'd also like to acknowledge my colleague from M...

*Press release* 13 March 2025

## **European Region reports highest number of measles cases in more than 25 years – UNICEF, WHO/Europe**

GENEVA/COPENHAGEN, 13 March 2025 – 127,350 measles cases were reported in the European Region in 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and UNICEF. Children under five accounted for more than 40 per cent of reported cases in the Region ...

*Remarks* 11 March 2025

## **Geneva Palais briefing note: Malnutrition tightening its grip on children in Rohingya refugee Camps**

DHAKA/GENEVA, 11 March 2025 – “Children in the world’s largest refugee camp are experiencing the worst levels of malnutrition since the massive displacement that occurred in 2017. “In February this year, admissions for severe acute malnutrition surged by over 27 per cent compared to the same month last year. “Th...

*Press release* 11 March 2025

## **27 per cent surge in number of children admitted for severe acute malnutrition treatment in Rohingya refugee camps**

DHAKA/COX’S BAZAR, Bangladesh, 11 March 2025 – The number of children needing emergency treatment for severe acute malnutrition in the Rohingya refugee camps in Bangladesh has surged by 27 per cent in February 2025 compared to the same period last year, as worsening conditions push more young children into life-th...

**Unitaid** [to 15 Mar 2025]

<https://unitaid.org/>

*Featured News*

*News releases*

## **Unitaid earns A+ rating in UK FCDO annual review, reinforcing its leadership in global health innovation**

11 March 2025

**Vaccine Equity Cooperative [nee Initiative]** [to 15 Mar 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 15 Mar 2025]

<https://www.vaccineacceptance.org/>

*News*

*Explainer*

## **Will climate change lead to more fungal infections?**

14 March 2025 7-minute read

**Vaccine Confidence Project** [to 15 Mar 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*



**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 15 Mar 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 15 Mar 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*Explainer*

**[Will climate change lead to more fungal infections?](#)**

14 March 2025 7-minute read

**The Wistar Institute** [to 15 Mar 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 15 Mar 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 15 Mar 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 15 Mar 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health [OIE]** [to 15 Mar 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [to 15 Mar 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 15 Mar 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 15 Mar 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [to 15 Mar 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 15 Mar 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*Expert insight*

**[Strong regulatory systems support the pharmaceutical industry in delivering better health outcomes](#)**

13 March 2025

Strong regulatory frameworks provide a predictable and efficient pathway for scientific advancements to translate into real-world impact, ultimately leading to better health outcomes for patients worldwide.

*Position paper* 11 Mar 2025

**[Trade and Health Agenda: A Meaningful World Trade Organization Roadmap to Strengthen Global Health](#)**

Ahead of the 14th WTO Ministerial Conference (MC14), trade associations representing the pharmaceutical industry provide a perspective on how WTO Members can a roadmap to strengthen global health through meaningful trade policies.

*External study* 11 Mar 2025

**[Value of investment on NCDs: Impact on health outcomes in low- and middle-income countries](#)**

In new research commissioned by IFPMA, Airfinity has determined that an additional investment of 1% of GDP toward domestic general government health expenditure in low- and middle-income countries (LMICs) would amount to a US\$ 310 billion additional investment, representing a 33% increase in current spending. This research is a response to the UHC 2030 action agenda...

*Press release* 11 March 2025

**[Pharmaceutical industry issues call for collective action to address the rising global burden of chronic disease](#)**

By IFPMA

- Non-communicable diseases (NCDs) including cancer, diabetes, cardiovascular disease, lung disease, mental health, and neurological disorders are responsible for 75% of deaths worldwide.

- New research demonstrates that investing an additional 1% of GDP in public healthcare spending, where at least 40% is aimed at preventing and treating NCDs, could save close to 5 million lives each year in low- and middle-income countries (LMICs).
- Ahead of the Fourth High-Level Meeting of the UN General Assembly on the prevention and control of NCDs and mental health this September, the global trade association representing the pharmaceutical industry urges collective action to reduce premature deaths from NCDs through existing cost-effective interventions.

### **International Alliance of Patients' Organizations – IAPO** [to 15 Mar 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

### **PhRMA** [to 15 Mar 2025]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

#### **AstraZeneca**

*Press Releases - No new digest content identified.*

#### **Bavarian Nordic**

*Latest News - No new digest content identified.*

#### **Bharat Biotech**

*Press Releases - No new digest announcements identified*

#### **BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified*

#### **Biological E**

*News - No new digest announcements identified*

#### **BioNTech**

*Press Releases*

**[BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update](#)**

10 March 2025

*[Excerpts from bulleted headlines]*

- Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies
- Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030
- Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different countries and regions and maintained global market leadership...

### **Boehringer**

Press Releases - No new digest announcements identified.

### **CanSinoBIO**

News - Website not responding at inquiry

### **CIGB**

Latest News - No new digest announcements identified.

### **CinnaGen**

Recent News - No new digest announcements identified.

### **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

### **Curevac**

News - No new digest announcements identified.

### **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

### **GSK**

Press releases for media

12 March 2025

[ViiV Healthcare's investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV](#)

12 March 2025

[ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP](#)

11 March 2025

[ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor \(INSTI\) and highly potent capsid inhibitor against HIV-1](#)

### **EuBiologics, S Korea**

News - No new digest announcements identified.

### **IMBCAMS, China**

Home - Website not responding at inquiry.

## **JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

## **Merck**

News releases

March 12, 2025

**Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48**

March 11, 2025

**Merck Unveils New Facility to Increase Vaccine Production Capacity**

*Opening highlights effort to expand U.S. manufacturing through a \$1 billion investment*

DURHAM, N.C.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, \$1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.

This expansion of our Durham plant is a crucial component of the more than \$12 billion Merck has invested toward U.S. capital investment since 2018 focused on expanding domestic manufacturing and research and development capabilities and creating new jobs in the U.S., with another \$8 billion of U.S. capital investment expected by 2028...

## **Moderna**

Press Releases - No new digest announcements identified

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases - No new digest announcements identified

## **Pfizer**

Recent Press Releases - No new digest announcements identified.

## **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

## **Sanofi Pasteur**

Press Releases - No new digest announcements identified.

## **Serum Institute**

News & Announcements - No new digest announcements identified.

## **Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

## **Sinovac**

Press Releases - No new digest announcements identified.

## **SK Biosciences**

[Press Releases](#)

### **[SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market](#)**

750,000 doses of influenza vaccine to be supplied to Southeast Asia and Latin America in the first half of the year. Expanded exports markets ensure year-round vaccine production, enhancing supply stability and cost efficiency. Company accelerates global market entry with in-house developed vaccines for influenza, varicella, shingles, and typhoid.

2025.03.12

## **Takeda**

[Newsroom](#) - No new digest announcements identified.

## **Valneva**

[Press Releases](#) - No new digest announcements identified.

## **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - [Website not responding [404 error]]

## **WestVac Biopharma**

[Media](#) - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....  
.....

### ***[Contents \[click to move among sections\]](#)***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### ***[Journal Watch](#)***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]



**AMA Journal of Ethics**

March 2025 Volume 27, Number 3: E167-236

<https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism>

***Issue Theme: Regret in the Moral Psychology of Surgical Professionalism***

Along a physician's training path to becoming a surgeon, there are few, if any, formal or structured opportunities to reflect upon regret experiences. But the influences regret can have in surgeons' practices is worth considering, given that some patients suffer poor outcomes despite surgeons' long-term training, sound decision-making, competent practice, best efforts, and good intentions. This theme issue investigates regret as an expression of a surgeon's moral psychological development and their deep internalization of their capacity to harm. This theme issue also considers how we should regard regret and its kindred moral emotions—loss, grief, remorse, shame, guilt—in surgical life, training, and practice.

**American Journal of Human Genetics**

Mar 06, 2025 Volume 112 Issue 3 p457-724

<https://www.cell.com/ajhg/current>

***This month in The Journal***

Alyson B. Barnes, Sara B. Cullinan

Publication of the 2023 NASEM report sparked discussions on the use of population descriptors in genetics and genomics research. Experts have offered guidance to researchers in various sub-fields, but little guidance has been provided for clinical laboratory settings. In this issue, Hatchell et al. build on their experience in clinical genomics laboratories to provide insight into the relevance of both conventional and ancestry-based population descriptors for genetic testing and reporting. There are advantages and disadvantages to the use of both types of descriptors.

**American Journal of Infection Control**

March 2025 Volume 53 Issue 3 p285-414

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

March 2025 Volume 68 Issue 3 p429-644

<https://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

March 2025 115(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 2 (Feb 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/2/tpmd.112.issue-2.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

February 2025 Volume 178, Issue 2

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 340 March 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C>

[New issue; No digest content identified]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 15 Mar 2025)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 15 Mar 2025)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 15 Mar 2025)

#### **[The efficacy of COVID-19 vaccination in cystic fibrosis patients: a systematic review](#)**

*This systematic review evaluates the efficacy and safety of COVID-19 vaccines in individuals with cystic fibrosis (CF). A systematic search of major databases conducted between December 2019 and January 2024 i...*

Authors: Azam Gholami Shahrehabak, Masoud Rezaei, Amirhossein Shahpar, Nazanin Zeinali Nezhad, Mohammad Sharifi Sarasyabi, Mohsen Nakhaie, Maryam Gholami Shahrehabak and Razman Arabzadeh Bahri

Citation: *BMC Infectious Diseases* 2025 25:358

Content type: Systematic Review Published on: 13 March 2025

#### **[Comparative study of stigma and discrimination among vaccinated and non-vaccinated COVID-19 survivors in Bangladesh](#)**

*This study investigates the stigmatized experiences of vaccinated and non-vaccinated COVID-19 survivors in Bangladesh, emphasizing the factors contributing to stigma, the lived realities of stigmatization, and...*

Authors: Tamanna Rashid, Shamsul Arefin, Mowsome Bhattacharjee and Ashraful Islam

Citation: *BMC Infectious Diseases* 2025 25:338

Content type: Research Published on: 10 March 2025

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 15 Mar 2025)

### **A scoping review of human genetic resources management policies and databases in high- and middle-low-income countries**

*This review examines global human genetic resources management, focusing on genetic data policies and repositories in high- and middle-low-income countries.*

Authors: Hongwei Liu, Yin Liu, Yanyan Zhao, Yingqi Ma, Qiong Chen, Huifang Xu, Xiaoyang Wang, Xiaoli Guo, Hong Wang, Zelong Chen, Shaokai Zhang and Binbin Han

Citation: *BMC Medical Ethics* 2025 26:37

Content type: Systematic Review Published on: 15 March 2025

### **Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases**

*Sickle cell disease (SCD) and Diamond-Blackfan anemia syndrome (DBAS) are two hereditary blood diseases that present significant challenges to patients, their caregivers, and the healthcare system.*

*Both condit...*

Authors: L. C. van Hooff, E.-M. Merz, A. S. Kidane Gebremeskel, J. A. de Jong, G. L. Burchell and J. E. Lunshof

Citation: *BMC Medical Ethics* 2025 26:36

Content type: Systematic Review Published on: 14 March 2025

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 15 Mar 2025)

### **Reduced risks of influenza-associated hospitalization and complications following vaccination among over 2 million older individuals: a nationwide study using target trial emulation framework**

*Current evidence on influenza vaccine effectiveness (VE), which is predominately derived from small high-risk older populations and focuses on specific influenza-related complications, might not be generalizab...*

Authors: Zi-Yang Peng, Yun-Ting Hua, Wan-Ting Huang, Jin-Shang Wu and Huang-Tz Ou

Citation: *BMC Medicine* 2025 23:157

Content type: Research Published on: 13 March 2025

### **Modifiable risk factors of vaccine hesitancy: insights from a mixed methods multiple population study combining machine learning and thematic analysis during the COVID-19 pandemic**

*Vaccine hesitancy, the delay in acceptance or reluctance to vaccinate, ranks among the top threats to global health. Identifying modifiable factors contributing to vaccine hesitancy is crucial for developing t...*

Authors: Omid V. Ebrahimi, Ella Marie Sandbakken, Sigrun Marie Moss, Sverre Urnes Johnson, Asle Hoffart, Sarah Bauermeister, Ole André Solbakken, Lars T. Westlye and Esten H. Leonardsen

Citation: *BMC Medicine* 2025 23:155

Content type: Research Published on: 12 March 2025

### **Research prioritisation in preparedness for and response to outbreaks of high-consequence pathogens: a scoping review**

*Priority setting for research on epidemic/pandemic-prone pathogens is essential for the allocation of limited resources to optimise impact. It involves the identification of gaps in knowledge crucial to effect...*

Authors: Emilia Antonio, Nicolas Pulik, Susan Khader Ibrahim, Adebisi Adenipekun, Shanthi Levanita, Isabel Foster, Dorothy Chepkirui, Eli Harriss, Louise Sigfrid and Alice Norton

Citation: *BMC Medicine* 2025 23:147

Content type: Research Published on: 10 March 2025

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 15 Mar 2025)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 15 Mar 2025)

#### **Longitudinal association between parents' reported vaccination program preferences and children's actual immunization patterns in Shanghai, China**

*As China expands its national immunization program, it is essential to understand parents' beliefs about pediatric vaccination programs and the translation into actual vaccination decision-making for their chi...*

Authors: Zhuoying Huang, Mengdi Ji, Matthew L. Boulton, Jia Ren, Xiaodong Sun and Abram L. Wagner

Citation: *BMC Public Health* 2025 25:999

Content type: Research Published on: 14 March 2025

#### **Vaccination coverage and its associated factors among children under-5 in Somalia**

*Despite global efforts to improve vaccination, the coverage of completing basic immunization (BCG, Polio 3, DPT 3, and Measles vaccines) remains unsatisfactory in Somalia. Limited research exists on the determ...*

Authors: Mohamed Said Hassan, Faruq Abdulla and Moyazzem Hossain

Citation: *BMC Public Health* 2025 25:997

Content type: Research Published on: 13 March 2025

#### **Vaccination and rheumatoid arthritis: an updated systematic review and meta-analysis of data from 25,949,597 participants**

*This systematic review and meta-analysis aimed to investigate the association between vaccinations and the risk of rheumatoid arthritis (RA), specifically addressing concerns about a potential increased risk a...*

Authors: Hejing Pan, Yin Yu, Xuanlin Li, Meijiao Wang, Chengping Wen, Qiaoding Dai and Lin Huang

Citation: *BMC Public Health* 2025 25:933

Content type: Research Published on: 10 March 2025

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 15 Mar 2025)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>

[Reviewed earlier]

### **BMJ Global Health**

February 2025 - Volume 10 - 2  
<https://gh.bmj.com/content/10/2>  
[Reviewed earlier]

### **Bulletin of the World Health Organization**

2025 Mar 1; 103(3)  
<https://www.who.int/publications/journals/bulletin/>  
[Reviewed earlier]

### **Cell**

Mar 06, 2025 Volume 188 Issue 5 p1175-1456  
<https://www.cell.com/cell/current>  
[Reviewed earlier]

### **Child Care, Health and Development**

Volume 51, Issue 2 March 2025  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 3 Pages: 599-857 March 2025  
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>  
[Reviewed earlier]

### **Clinical Therapeutics**

March 2025 Volume 47 Issue 3 p179-248  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 1, February 2025  
<https://journals.sagepub.com/toc/ctja/22/1>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 15 Mar 2025]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 150 March 2025  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/150/suppl/C>  
[Reviewed earlier]

### **The CRISPR Journal**

Volume 8, Issue 1 / February 2025

<https://www.liebertpub.com/toc/crispr/8/1>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Science and Society: Pathways to Equitable Access and Delivery of Genomics Medicine in Africa](#)

Nchangwi Syntia Munung

*REVIEW Open access* 24 February 2025

### **Current Medical Research and Opinion**

Volume 41, Issue 1 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Developing World Bioethics**

Volume 25, Issue 1 Pages: 1-79 March 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

### **Development Policy Review**

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]



## **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

## **Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

## **EMBO Reports**

Volume 26 Issue 5 10 March 2025

<https://www.embopress.org/toc/14693178/current>

*Science & Society* 27 February 2025

**[Next-generation biotechnology inspired by extremes: The potential of extremophile organisms for synthetic biology and for more efficient and sustainable biotechnology](#)**

Shuang Zheng, et al.

Research on and exploitation of the genetic diversity of bacteria adapted to thrive under extreme conditions holds great potential for biotechnology to develop more efficient, cheaper and more sustainable production processes.

## **Emerging Infectious Diseases**

Volume 31, Number 2—February 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

## **Epidemics**

Volume 50 March 2025

<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>

[New issue; No digest content identified]

## **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Moral distress in clinical research • Research with incarcerated and homeless women***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>  
[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>  
[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>  
[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

### **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>  
*Special Section*

***Will Trump Change the World?***

### **Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 1, January 2025

<https://www.nature.com/gt/volumes/32/issues/1>  
[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 3 March 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/3>  
[New issue; No digest content identified]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 2, March 2025

<https://academic.oup.com/heapol/issue/40/2>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 15 Mar 2025]

[No new digest content identified]

## **Human Gene Therapy**

Volume 36, Issue 5-6 / March 2025

<https://www.liebertpub.com/toc/hum/36/5-6>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

## **Immunity**

Feb 11, 2025 Volume 58 Issue 2 p265-514

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 15 Mar 2025]

### **[Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded](#)**

Several high-risk types of human papillomaviruses (HPVs) are associated with cervical cancer and other malignancies. Despite the tremendous success of marketed prophylactic HPV vaccines for the past 18 years, ...

Authors: Sogand Amiri, Shiva Rasekh, Seyed Mohammad Iman Moezzi, Nadia Seifi, Seyed Amirreza Fatemi, Shirin Fathi, Ashkan Bagheri and Manica Negahdaripour

Citation: *Infectious Agents and Cancer* 2025 20:16

Content type: Review Published on: 10 March 2025

## **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>  
[Accessed 15 Mar 2025]  
[No new digest content identified]

### **International Health**

Volume 17, Issue 2, March 2025

<https://academic.oup.com/inthealth/issue/17/2>

*Original Articles*

#### **[Human papillomavirus vaccine coverage among immigrant adolescents in Alberta: a population-based cohort study](#)**

Crystal Du and others

*International Health*, Volume 17, Issue 2, March 2025, Pages 179–185,

<https://doi.org/10.1093/inthealth/ihae038>

#### **[Active surveillance of immunization adverse effects: a multicentre, open-label, three-arm randomized uncontrolled trial in Ethiopia](#)**

Dawit Getachew Assefa and others

*International Health*, Volume 17, Issue 2, March 2025, Pages 195–204,

<https://doi.org/10.1093/inthealth/ihae040>

#### **[COVID-19 vaccine wastage in private and public healthcare facilities in KwaZulu-Natal, South Africa](#)**

Viloshini Krishna Manickum and Lehlohonolo John Mathibe

*International Health*, Volume 17, Issue 2, March 2025, Pages 229–231,

<https://doi.org/10.1093/inthealth/ihae056>

### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 2 (2025): February 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/121>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 54, Issue 1, February 2025

<https://academic.oup.com/ije/issue/54/1>

[New issue; No digest content identified]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

*Table of contents*

[Reviewed earlier]

## **JAMA**

March 11, 2025, Vol 333, No. 10, Pages 827-917

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

## **JAMA Health Forum**

March 2025, Vol 6, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

Editorial

### **The US, the World Health Organization, and the Global Health Infrastructure**

Sandro Galea, MD, DrPH

... The second Trump Administration similarly withdrew from the WHO during its first week in office. This immediately threatened the function of the WHO. The WHO Director-General subsequently issued a hiring freeze, and noted a range of consequences that US withdrawal may have on the capacity of the WHO to carry out its mission.<sup>4</sup>

Academic analysis has also noted a range of harmful consequences that may follow the US withdrawal from the WHO.<sup>5</sup> These include, but are certainly not limited to, having less access to surveillance data needed to anticipate outbreaks and losing influence on what remains the world's most important health agency. The global consequences may be even more severe given the funding cuts, threatening the organization's ability to function effectively, particularly during global health crises. Therefore, the US finds itself at a worrisome inflection point in its alignment with global health infrastructure. Time will tell whether the anticipated consequences—for the US and global health—of disengagement from the WHO will emerge, but if they do, they will be an unfortunate and self-inflicted undercutting of US leadership in global health.

## **JAMA Pediatrics**

February 2025, Vol 179, No. 2, Pages 111-224

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBI Evidence Synthesis**

March 2025 - Volume 23 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

## **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

*Contents*

[New issue; No digest content identified]

**Journal of Community Health**

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

**Journal of Development Economics**

Volume 173 March 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 2 Pages: 1-619 March 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

**Journal of Medical Ethics**

March 2025 - Volume 51 - 3

<http://jme.bmj.com/content/current>

[New issue; No digest content identified]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

March/April 2025 - Volume 31 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 4, December 2024



<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

March 2025 Volume 22 Issue 224

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 32, Issue 2, March 2025

<https://academic.oup.com/jtm/issue>

*Editor's Choice*

**[First clinical experiences with the tetravalent live vaccine against dengue \(Qdenga®\) in travellers: a multicentric TravVacNet study in Germany](#)**

Clara Köpke and others

*Journal of Travel Medicine*, Volume 32, Issue 2, March 2025, taaf004,

<https://doi.org/10.1093/jtm/taaf004>

*Editor's Choice*

**[Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults](#)**

Deborah J Mills and others

*Journal of Travel Medicine*, Volume 32, Issue 2, March 2025, taaf006,

<https://doi.org/10.1093/jtm/taaf006>

### **Journal of Virology**

Volume 99 • Number 2 • February 2025

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

### **The Lancet**

Mar 15, 2025 Volume 405 Number 10482 p867-950

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Mar 2025 Volume 9 Number 3 p151-210, e4-e9

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Mar 2025 Volume 7 Number 3 e167-e231

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Mar 2025 Volume 13 Number 3 e372-e598

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Mar 2025 Volume 25 Number 3 p243-356, e114-e190

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Mar 2025 Volume 10 Number 3 e165-e263

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Mar 2025 Volume 13 Number 3 p189-288, e17-e19

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 29, Issue 2 February 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 45 Issue 2, February 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Molecular Therapy**

Mar 05, 2025 Volume 33 Issue 3 p825-1304

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

**Nature**

Volume 639 Issue 8054, 13 March 2025

<https://www.nature.com/nature/volumes/638/issues/8054>

*Editorial* 10 Mar 2025

**Science diplomacy can help to heal global rifts — if research is respected**

The universal language of science allows nations to reach a mutual understanding of shared problems. But that requires politicians not to meddle in how science is done.

*Perspective* 09 Dec 2024

**A framework for neural organoids, assembloids and transplantation studies**

Sergiu P. Paşca, Paola Arlotta, Tracy Young-Pearse

**Abstract**

As the field of neural organoids and assembloids expands, there is an emergent need for guidance and advice on designing, conducting and reporting experiments to increase the reproducibility and utility of these models. In this Perspective, we present a framework for the experimental process that encompasses ensuring the quality and integrity of human pluripotent stem cells, characterizing and manipulating neural cells in vitro, transplantation techniques and considerations for modelling human development, evolution and disease. As with all scientific endeavours, we advocate for rigorous experimental designs tailored to explicit scientific questions as well as transparent methodologies and data sharing to provide useful knowledge for current research practices and for developing regulatory standards.

**Nature Biotechnology**

Volume 43 Issue 2, February 2025

<https://www.nature.com/nbt/volumes/43/issues/2>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 15 Mar 2025)

[Reviewed earlier]

**Nature Genetics**

Volume 57 Issue 3, March 2025

<https://www.nature.com/ng/volumes/57/issues/3>

*Comment* 03 Mar 2025

**The Federated European Genome–Phenome Archive as a global network for sharing human genomics data**

In this era of rapidly expanding human genomics in research and healthcare, efficient data reuse is essential to maximize benefits for society. In response, the Federated European Genome–Phenome Archive (FEGA) was launched in 2022, and as of 2024, the FEGA network was composed of seven national nodes. Here we describe the complexities, challenges and achievements of FEGA, unravelling the dynamic interplay of regulatory frameworks, technical challenges and the shared vision of advancing genomic research.

Teresa D’Altri, Mallory Ann Freeberg, Thomas M. Keane

*Perspective* 03 Feb 2025

**Genomics of rare diseases in the Greater Middle East**

The Greater Middle East is home to a rich genetic diversity that remains largely untapped in genomic research. This Perspective explores its potential for rare disease research, obstacles limiting progress and strategies to drive genomic discoveries.

Ikram Chekroun, Shruti Shenbagam, Ahmad N. Abou Tayoun

### **Nature Human Behaviour**

Volume 9 Issue 2, February 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/2>

[Reviewed earlier]

### **Nature Medicine**

Volume 31 Issue 2, February 2025

<https://www.nature.com/nm/volumes/31/issues/2>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 24 Issue 3, March 2025

<https://www.nature.com/nrd/volumes/24/issues/3>

*Comment* 17 Dec 2024

#### **Open Targets: 10 years of partnership in target discovery**

The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifying and prioritizing therapeutic targets. We highlight key achievements and insights stemming from this partnership of academic and industry scientists.

David G. Hulcoop, Gosia Trynka, Ellen M. McDonagh

### **Nature Reviews Genetics**

Volume 26 Issue 3, March 2025

<https://www.nature.com/nrg/volumes/26/issues/3>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 25 Issue 3, March 2025

<https://www.nature.com/nri/volumes/25/issues/3>

[Reviewed earlier]

### **New England Journal of Medicine**

Volume 392 No. 11 March 13/20, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

### **NEJM Evidence**

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>  
[Accessed 15 Mar 2025]  
[No new digest content identified]

### **Pediatrics**

Volume 155, Issue 3 March 2025  
<https://publications.aap.org/pediatrics/issue/155/3>  
[Reviewed earlier]

### **PharmacoEconomics**

Volume 43, Issue 3 March 2025  
<https://link.springer.com/journal/40273/volumes-and-issues/43-3>  
[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>  
(Accessed 15 Mar 2025)  
[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 15 Mar 2025)  
[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 15 Mar 2025)

#### **[Willingness to be vaccinated against COVID-19 and associated factors in Migori County, Kenya: Analysis of cross-sectional observational survey data](#)**

Gianna Ferrara, Sandra Mudhune, Ash Rogers, Julius Mbeya, Alyn Achieng, Vincent Were, Constance Shumba, Alice Muga, Joseph Starnes  
Research Article | published 13 Mar 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003699>

#### **[Understanding the expectations, positions and ambitions of LMICs during pandemic treaty negotiations, and the factors contributing to them](#)**

Greta Cranston  
Research Article | published 12 Mar 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003851>

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>  
(Accessed 15 Mar 2025)  
[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

[Accessed 15 Mar 2025]

### **Assessing the global dengue burden: Incidence, mortality, and disability trends over three decades**

Wei-Xian Zhang, Tian-Yu Zhao, Cun-Chen Wang, Yong He, Hong-Zheng Lu, Hai-Ting Zhang, Lin-Min Wang, Mao Zhang, Chun-Xiao Li, Sheng-Qun Deng

Research Article | published 12 Mar 2025 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0012932>

## **PLoS One**

<http://www.plosone.org/>

[Accessed 15 Mar 2025]

### **Prevalence and pattern of adverse events following COVID-19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria**

Habibullah Adamu, Sufyanu Lawal, Ishaka Alhaji Bawa, Akilu Muhammad Sani, Adamu Ahmed Adamu

Research Article | published 12 Mar 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0277585>

### **Perspectives of stakeholders on barriers to COVID-19 protective behaviors adherence and vaccination among Myanmar migrant workers in southern Thailand: A qualitative study**

Hein Htet, Wit Wichaidit, Aungkana Chuaychai, Tiida Sottiyotin, Kyaw Ko Ko Htet, Hutcha Sriplung, Virasakdi Chongsuvivatwong

Research Article | published 11 Mar 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0317714>

### **Factors associated with uptake of human papilloma virus vaccine among adolescent girls: A cross sectional survey on insights into HPV Infection Prevention in Kabarole District, Western Uganda**

Solomon Asiimwe, Fred N. Bagenda, Tony Mugisa

Research Article | published 10 Mar 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0306960>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 15 Mar 2025]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

March 18, 2025 | vol. 122 | no. 11

<https://www.pnas.org/toc/pnas/122/10>

[New issue; No digest content identified]

## **PNAS Nexus**

Volume 4, Issue 2, February 2025

<https://academic.oup.com/pnasnexus/issue/4/2>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 39 - Issue 6 - December 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

March 2025 Volume 292 Issue 2042

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 240 Pages 1-222 (March 2025)

<https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

### **Public Health Reports**

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 35 Issue 3, March 2025

<https://journals.sagepub.com/toc/QHR/current>

*Research article* First published August 27, 2024 pp. 349–365

**[Barriers to Childhood Immunization in Rural and Remote Areas: A Qualitative Exploration From the Perspectives of Community Leaders in Sindh, Pakistan](#)**

Sundeep Sahit, et al.

## **Research Ethics**

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 15 Mar 2025]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 45, Issue 2 pages: 265-472 February 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 15 Mar 2025]

[No new digest content identified]

## **Royal Society Open Science**

March 2025 Volume 12 Issue 3

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

## **Science**

Volume 387| Issue 6739| 14 Mar 2025

<https://www.science.org/toc/science/current>

*Editorial*

[\*\*Uphold US-Canada science\*\*](#)

BY Rémi Quirion

13 Mar 2025

## **Science and Engineering Ethics**

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]



### **Science Translational Medicine**

Volume 17| Issue 789| 12 Mar 2025

<https://www.science.org/toc/stm/current>

Volume 17| Issue 789| 12 Mar 2025

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Social Science & Medicine**

Volume 370 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C>

[No new digest content identified]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 46, Issue 1 February 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-1>

#### ***Special Issue on Bioethics and Language***

Issue Editor: Matthew Vest

[New issue; No digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 51 2 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/51/suppl/C>

*Discussion Abstract only*

#### **[The origin of vaccine nationalism](#)**

Qi Shao

Article 126897

### *Highlights*

:: There is a serious conflict between medical and political ethics over the global COVID-19 vaccine distribution, which has created a rift between the medical and political communities.  
:: Vaccine nationalism originates from the reality that political ethics dominate global vaccine distribution during a pandemic.  
:: As long as political ethics dominate global vaccine distribution, vaccine nationalism is an ideology common to countries.  
:: Countries differ only in their capacity to prioritise vaccinating their populations, not in their willingness to do so, let alone in their level of morality.  
:: We need to respond to vaccine nationalism by improving national capacity and technology related to vaccines, not by persuading countries to change this ideology.

### *Review article Abstract only*

#### **[Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs](#)**

Darvin S. Smith, Maarten Postma, David Fisman, Joaquin Mould-Quevedo  
Article 126879

### *Research article Abstract only*

#### **[Implementation of mid-adult HPV vaccination guidelines into clinical practice](#)**

Erika L. Thompson, Idara N. Akpan, Sarah Alkhatib, Jessica Grace, ... Christopher W. Wheldon  
Article 126867

### *Research article Open access*

#### **[Global production capacity of seasonal and pandemic influenza vaccines in 2023](#)**

Jessica Taaffe, Shoshanna Goldin, Philipp Lambach, Erin Sparrow  
Article 126839

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 15 Mar 2025]

### *Open Access Perspective*

#### **[The Mpox Response Among Key Populations at High Risk of or Living with HIV in Rwanda: Leveraging the Successful National HIV Control Program for More Impactful Interventions](#)**

by Gallican Rwibasira, Tafadzwa Dzinamarira, Jean Claude Semuto Ngabonziza, Albert Tuyishime, Ayman Ahmed and Claude Mambo Muvunyi

Vaccines 2025, 13(3), 307; <https://doi.org/10.3390/vaccines13030307> - 13 Mar 2025

### *Abstract*

Mpox, an emerging zoonotic infectious disease, presents a significant public health threat, especially among high-risk groups like female sex workers and men who have sex with men. This commentary reviews and summarizes Rwanda's response to mpox, focusing on its intersection with HIV. Rwanda [...]

### *Open Access Article*

#### **[Impact of Measles, Mumps, and Rubella Vaccination on Hospitalizations and Human Capital: Evidence from Copenhagen School Health Records](#)**

by Onur Altindag, Jane Greve and Erdal Tekin

Vaccines 2025, 13(3), 302; <https://doi.org/10.3390/vaccines13030302> - 11 Mar 2025

### *Abstract*

Background: This paper investigates the long-term effects of the measles, mumps, and rubella (MMR) vaccine on healthcare, education, and economic outcomes using a novel dataset from the Copenhagen

School Health Records Register. Methods: To address potential endogeneity, we use within-sibling variation in vaccination [...]

## Value in Health

March 2025 Volume 28 Issue 3p323-488

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

## World Development

Volume 187 March 2025

<https://www.sciencedirect.com/journal/world-development/vol/187/suppl/C>

[Reviewed earlier]

.....  
.....

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Pre-Print Servers**

### **arxiv**

<https://arxiv.org/>

[Accessed 15 Mar 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[arXiv:2503.09639](https://arxiv.org/abs/2503.09639) (cross-list from cs.MA) [pdf, html, other]

### **[Can A Society of Generative Agents Simulate Human Behavior and Inform Public Health Policy? A Case Study on Vaccine Hesitancy](#)**

[Abe Bohan Hou](#), [Hongru Du](#), [Yichen Wang](#), [Jingyu Zhang](#), [Zixiao Wang](#), [Paul Pu Liang](#), [Daniel Khashabi](#), [Lauren Gardner](#), [Tianxing He](#)

Can we simulate a sandbox society with generative agents to model human behavior, thereby reducing the over-reliance on real human trials for assessing public policies? In this work, we investigate the feasibility of simulating health-related decision-making, using vaccine hesitancy, defined as the delay in acceptance or refusal of vaccines despite the availability of vaccination services (MacDonald, 2015), as a case study. To this end, we introduce the VacSim framework with 100 generative agents powered by Large Language Models (LLMs). VacSim simulates vaccine policy outcomes with the following steps: 1) instantiate a population of agents with demographics based on census data; 2) connect the agents via a social network and model vaccine attitudes as a function of social dynamics and disease-related information; 3) design and evaluate various public health interventions aimed at mitigating vaccine hesitancy. To align with real-world results, we also introduce simulation warmup and attitude modulation to adjust agents' attitudes. We propose a series of evaluations to assess the reliability of various LLM simulations. Experiments indicate that models like

Llama and Qwen can simulate aspects of human behavior but also highlight real-world alignment challenges, such as inconsistent responses with demographic profiles. This early exploration of LLM-driven simulations is not meant to serve as definitive policy guidance; instead, it serves as a call for action to examine social simulation for policy development.

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 15 Mar 2025]

[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 15 Mar 2025]

[Filter: All articles]

#### **[Community Perspectives on COVID-19 Vaccine Allocation Ethical Principles in Uganda: A Descriptive Cross-Sectional Study](#)**

Juliet Kiguli, Stuart Ssebubbu, Joyce Nabaliisa, Celia Nalwadda, Bob Ramadhan Kirunda, Mooka Kamweri

medRxiv 2025.03.12.25323855; doi: <https://doi.org/10.1101/2025.03.12.25323855>

#### *Abstract*

The COVID-19 pandemic has posed significant challenges globally, necessitating the rapid development and distribution of vaccines. This study aimed to engage community members in Uganda to understand their perceptions of the ethical principles and prioritisation criteria for COVID-19 vaccine allocation. Employing a mixed-method approach of quantitative survey and qualitative key informant interviews, the study yielded significant findings crucial for understanding community perspectives on COVID-19 vaccine allocation in Uganda. This study investigated Ugandan community perspectives on the ethical principles governing COVID-19 vaccine allocation. While 82% of respondents were familiar with vaccination guidelines, vaccine hesitancy was evident due to mistrust, concerns about information quality, preference for alternative medicine, and doubts regarding vaccine efficacy. Despite general support for ethical principles, many participants doubted the government's ability to ensure equitable vaccine distribution. Concerns about fairness and global equity for low-middle-income countries were raised, emphasising the need to address cost, corruption, and political influence. The study highlights the importance of contextualising and localising ethical principles to enhance their relevance and acceptance within communities. Effective communication, community engagement, and addressing underlying sociocultural and systemic barriers are crucial for successful vaccine deployment. Incorporating community perspectives can foster trust and ownership, ultimately improving vaccine uptake and pandemic response.

#### **[Architecture of systems affecting disease trajectories in a conflict zone: A community-centered systems inquiry in North Gaza](#)**

Yahya Shaikh, Mohammed O. A. Hamouda, Shatha Elnakib

medRxiv 2025.03.11.25323741; doi: <https://doi.org/10.1101/2025.03.11.25323741>

Humanitarian crises, particularly in conflict zones, create cascading disruptions that impact every aspect of daily life, including health and disease outcomes. While international humanitarian frameworks categorize these crises into discrete operational clusters, affected populations experience them as interwoven, systemic failures. This study examines how conflict-induced disruptions transform a preventable and typically self-limiting disease—Hepatitis A—into a fatal outcome in North Gaza...

#### **[From Research to Impact: Assessing a Decade of CDC's Public Health Science by Topic Area, 2014-2023](#)**

Joy Ortega, Martha Knuth, Victoria E. Dunkley, Christie Kim, Elissa Meites, Brian B. Yoo, Katlyn Wainwright, Bao-Ping Zhu, Mary G. Reynolds  
medRxiv 2025.03.07.25323572; doi: <https://doi.org/10.1101/2025.03.07.25323572>

This study provides an objective, in-depth overview of a large body of science output addressing public health. We apply topic modeling and bibliometric tools to explore the relevance and impact of a decade of CDC-authored publications. Methods: We identified 34,104 scientific publications from 2014-2023 with  $\geq 1$  CDC-affiliated author using Science Clips, a CDC library database...Publications in this collection addressed an array of public health topic themes and demonstrated resonance within academic and policy arenas as well as with the public.

### **Impact of an international HIV funding crisis on HIV infections and mortality in low- and middle-income countries: a modelling study**

Debra ten Brink, Rowan Martin-Hughes, Anna Bowring, Nisaa Wulan, Kelvin Burke, Tom Tidhar, Shona Dalal, Nick Scott  
medRxiv 2025.02.27.25323033; doi: <https://doi.org/10.1101/2025.02.27.25323033> Revision

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>  
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]  
[Website not responding at inquiry]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>  
[Accessed 15 Mar 2025]  
[No new digest content identified]

\* \* \* \*

### **Think Tanks**

**Brookings** [to 15 Mar 2025]  
<http://www.brookings.edu/>  
*Reports, Events*  
*No new digest content identified.*

**Center for Global Development** [to 15 Mar 2025]  
<https://www.cgdev.org/>  
*All Research*  
*No new digest content identified.*

**Chatham House** [to 15 Mar 2025]  
<https://www.chathamhouse.org/>  
*Selected Analysis, Comment, Events*  
*No new digest content identified.*

**Council on Foreign Relations** [to 15 Mar 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 15 Mar 2025]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 15 Mar 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Poll: Most Republicans Do Not Trust CDC On Bird Flu](#)**

March 13, 2025 *News Release*

As bird flu continues to circulate among animals in the U.S. with some human cases, about six in 10 (58%) people overall have at least “a fair amount” of trust in the Centers for Disease Control and Prevention (CDC) to provide reliable information about bird flu, though only 21% have...

**McKinsey Global Institute** [to 15 Mar 2025]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 15 Mar 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 15 Mar 2025]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 15 Mar 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Expert Insights* Mar 10, 2025

**[Policy Options to Prevent the Creation of Mirror Organisms](#)**

Ongoing research could lead to the creation of mirror organisms, whose molecular components are mirror images of those found in nature. This paper examines policy options to prevent their creation, given the potential risks such organisms pose.

**Urban Institute** [to 15 Mar 2025]

<https://www.urban.org/publications>

## New Research Publications - Selected

**World Economic Forum** [to 15 Mar 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

*	*	*	*
*	*	*	*

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\*  
\*

\*  
\*

\*  
\*

\*  
\*